Prevention and treatment of relapse after hematopoietic stem cell transplantation in acute myeloid leukemia
-
-
Key words:
- acute myeloid leukemia /
- hematopoietic stem cell transplantation /
- relapse /
- prevention /
- therapy
-
-
[1] Zeiser R, Beelen DW, Bethge W, et al. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(4): e128-e140. doi: 10.1016/j.bbmt.2019.01.016
[2] Webster JA, Luznik L, Gojo I. Treatment of AML Relapse after Allo-HCT[J]. Front Oncol, 2021, 11: 812207. doi: 10.3389/fonc.2021.812207
[3] Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission[J]. J Clin Oncol, 2016, 34(4): 329-336. doi: 10.1200/JCO.2015.63.3826
[4] Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. doi: 10.1182/blood-2016-08-733196
[5] Ertz-Archambault N, Kosiorek H, Slack JL, et al. Cytogenetic evolution in myeloid neoplasms at relapse after allogeneic hematopoietic cell transplantation: association with previous chemotherapy and effect on survival[J]. Biol Blood Marrow Transplant, 2017, 23(5): 782-789. doi: 10.1016/j.bbmt.2017.02.003
[6] Christopher MJ, Petti AA, Rettig MP, et al. Immune escape of relapsed AML cells after allogeneic transplantation[J]. N Eng J Med, 2018, 379(24): 2330-2341. doi: 10.1056/NEJMoa1808777
[7] Hutten TJA, Norde WJ, Woestenenk R, et al. Increased coexpression of PD-1, TIGIT and KLRG-1 on tumor-reactive CD8+ T cells during relapse after stem transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(4): 666-677. doi: 10.1016/j.bbmt.2017.11.027
[8] Kroger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase Ⅲ study of the EBMT(RICMAC Trial)[J]. J Clin Oncol, 2017, 35(19): 2157-2164. doi: 10.1200/JCO.2016.70.7349
[9] Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes[J]. J Clin Oncol, 2017, 35(11): 1154-1161. doi: 10.1200/JCO.2016.70.7091
[10] Wang L, Devillier R, Wan M, et al. Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai lnstitute of Hematology and Institut Paoli-Calmettes[J]. Bone Marrow Transplant, 2019, 54(3): 458-464. doi: 10.1038/s41409-018-0283-5
[11] 中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅱ)—移植后白血病复发(2016年版)[J]. 中华血液学杂志, 2016, 37(10): 846-851. doi: 10.3760/cma.j.issn.0253-2727.2016.10.004
[12] 中国临床肿瘤学会指南工作委员会. 异基因造血干细胞移植治疗白血病和骨髓增生异常综合征指南2021[M]. 北京: 人民卫生出版社, 2021: 144-160.
[13] Garcia JS, Kim HT, Murdock HM, et al. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active[J]. Blood Adv, 2021, 5(24): 5536-5545. doi: 10.1182/bloodadvances.2021005566
[14] Li ZY, Shi W, Lu X, et al. Decitabine-Intensified Modified Busulfan/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis[J]. Front Oncol, 2022, 12: 844937. doi: 10.3389/fonc.2022.844937
[15] Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized double-blind phase Ⅲ clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation[J]. J Clin Oncol, 2017, 35(36): 4003-4011. doi: 10.1200/JCO.2017.75.8177
[16] Devillier R, Labopin M, Chevallier P, et al. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation[J]. Bone Marrow Transplant, 2018, 53(4): 431-437. doi: 10.1038/s41409-017-0043-y
[17] Modi D, Kondrat K, Kim S, et al. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome[J]. Transplant Cell Ther, 2021, 27(9): 760-767. doi: 10.1016/j.jtct.2021.06.018
[18] Wei YX, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome[J]. Cancer Sci, 2021, 112(9): 3636-3644. doi: 10.1111/cas.15048
[19] Pham B, Hoeg R, Krishnan R, et al. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. Bone Marrow Transplant, 2021, 56(12): 2975-2980. doi: 10.1038/s41409-021-01444-1
[20] Bug G, Burchert A, Wagner EM, et al. Phase Ⅰ/Ⅱ study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML(PANOBEST trial)[J]. Leukemia, 2017, 31(11): 2523-2525. doi: 10.1038/leu.2017.242
[21] Burchert A, Bug G, Fritz LV, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation(SORMAIN)[J]. J Clin Oncol, 2020, 38(26): 2993-3002. doi: 10.1200/JCO.19.03345
[22] Gao XN, Lin J, Wang LJ, et al. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia[J]. Ann Hematol, 2019, 98(5): 1267-1277. doi: 10.1007/s00277-019-03636-8
[23] Schuler E, Wagner-Drouet EM, Ajib S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group[J]. Ann Hematol, 2021, 100(4): 959-968. doi: 10.1007/s00277-020-04321-x
[24] Metzelder SK, Schroeder T, Lubbert M, et al. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation[J]. Eur J Cancer, 2017, 86: 233-239. doi: 10.1016/j.ejca.2017.09.016
[25] Mo XD, Zhang XH, Xu LP, et al. Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation[J]. Front Med, 2019, 13(2): 238-249. doi: 10.1007/s11684-017-0599-3
[26] Craddock C, Slade D, Santo CD, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia[J]. J Clin Oncol, 2019, 37(7): 580-588. doi: 10.1200/JCO.18.00889
[27] Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation[J]. N Engl J Med, 2016, 375(2): 143-153. doi: 10.1056/NEJMoa1601202
[28] Albring JC, Inselmann S, Sauer T, et al. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation[J]. Bone Marrow Transplant, 2017, 52(2): 317-320. doi: 10.1038/bmt.2016.274
[29] Koren-Michowitz M, Maayan H, Apel A, et al. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation[J]. Ann Hematol, 2015, 94(3): 375-378. doi: 10.1007/s00277-014-2229-3
[30] Yang F, Li ZH, Dong CW, et al. Daratumumab and Venetoclax-Containing Regimens in the Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies[C]. 2020 ASH Annual Meeting, Abstract #2407.
[31] Lamure S, Paul F, Gagez AL, et al. A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment[J]. J Clin Med, 2020, 9(7): 2204. doi: 10.3390/jcm9072204
[32] Shah N, Rakszawski K, Nickolich M, et al. Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion[J]. Ann Hematol, 2021, 100(10): 2585-2592. doi: 10.1007/s00277-021-04616-7
[33] Schroeder T, Rautenberg C, Krüger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group[J]. Ann Hematol, 2018, 97(2): 335-342. doi: 10.1007/s00277-017-3185-5
[34] Cui QY, Qian CS, Xu N, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. J Hematol Oncol, 2021, 14(1): 82. doi: 10.1186/s13045-021-01092-4
[35] Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse[J]. JAMA Oncol, 2018, 4(9): 1245-1253. doi: 10.1001/jamaoncol.2018.2091
-
计量
- 文章访问数: 1622
- PDF下载数: 1999
- 施引文献: 0
下载: